These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 2408194)
61. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
62. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439 [TBL] [Abstract][Full Text] [Related]
63. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425 [TBL] [Abstract][Full Text] [Related]
64. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. Soriano-Gabarró M; Rosenstein N; LaForce FM J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780 [TBL] [Abstract][Full Text] [Related]
65. [Clinical trials of the new Norwegian vaccine against diseases caused by Meningococcus B]. Bjune G; Nøkleby H; Hareide B Tidsskr Nor Laegeforen; 1990 Feb; 110(5):614-7. PubMed ID: 2408194 [TBL] [Abstract][Full Text] [Related]
66. Meningococcal serogroup B infections: a search for a broadly protective vaccine. Vermont CL; van den Dobbelsteen GP Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328 [TBL] [Abstract][Full Text] [Related]
67. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Okoko BJ; Idoko OT; Adegbola RA Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025 [TBL] [Abstract][Full Text] [Related]
69. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040 [TBL] [Abstract][Full Text] [Related]
71. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Marc LaForce F; Ravenscroft N; Djingarey M; Viviani S Vaccine; 2009 Jun; 27 Suppl 2():B13-9. PubMed ID: 19477559 [TBL] [Abstract][Full Text] [Related]
73. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Prasad K; Karlupia N Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408 [TBL] [Abstract][Full Text] [Related]
74. [Meningococcal disease in the Netherlands: media hype, but not an epidemic]. van Furth AM; Zaaijer HL Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168 [TBL] [Abstract][Full Text] [Related]
76. [Meningococcal disease in Africa--epidemiology and prevention]. Norheim G; Rosenqvist E; Aavitsland P; Caugant DA Tidsskr Nor Laegeforen; 2000 Jun; 120(15):1735-9. PubMed ID: 10904659 [TBL] [Abstract][Full Text] [Related]
77. Challenges and progress in the development of a serogroup B meningococcal vaccine. Lewis S; Sadarangani M; Hoe JC; Pollard AJ Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754 [TBL] [Abstract][Full Text] [Related]
78. Development of a meningococcal vaccine. Poolman JT Infect Agents Dis; 1995 Mar; 4(1):13-28. PubMed ID: 7728353 [No Abstract] [Full Text] [Related]